OncoCyte (OCX) Competitors $2.19 -0.02 (-0.90%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends OCX vs. PBYI, TIL, BDTX, GALT, ELUT, CGEN, TELO, JATT, ENTA, and MNPRShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Puma Biotechnology (PBYI), Instil Bio (TIL), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Elutia (ELUT), Compugen (CGEN), Telomir Pharmaceuticals (TELO), JATT Acquisition (JATT), Enanta Pharmaceuticals (ENTA), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Puma Biotechnology Instil Bio Black Diamond Therapeutics Galectin Therapeutics Elutia Compugen Telomir Pharmaceuticals JATT Acquisition Enanta Pharmaceuticals Monopar Therapeutics OncoCyte (NASDAQ:OCX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation. Do analysts rate OCX or PBYI? OncoCyte presently has a consensus price target of $4.42, suggesting a potential upside of 101.67%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 154.55%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Puma Biotechnology is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of OCX or PBYI? 55.3% of OncoCyte shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is OCX or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to OncoCyte's net margin of -6,122.29%. Puma Biotechnology's return on equity of 41.60% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-6,122.29% -269.32% -59.71% Puma Biotechnology 9.56%41.60%10.71% Does the media refer more to OCX or PBYI? In the previous week, Puma Biotechnology had 1 more articles in the media than OncoCyte. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for OncoCyte. Puma Biotechnology's average media sentiment score of 1.45 beat OncoCyte's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment OncoCyte Neutral Puma Biotechnology Positive Does the MarketBeat Community prefer OCX or PBYI? Puma Biotechnology received 541 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 67.07% of users gave Puma Biotechnology an outperform vote while only 8.65% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes98.65%Underperform Votes9591.35% Puma BiotechnologyOutperform Votes55067.07% Underperform Votes27032.93% Which has more volatility & risk, OCX or PBYI? OncoCyte has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Which has preferable earnings & valuation, OCX or PBYI? Puma Biotechnology has higher revenue and earnings than OncoCyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$709K52.00-$27.78MN/AN/APuma Biotechnology$243.57M0.55$21.59M$0.485.73 SummaryPuma Biotechnology beats OncoCyte on 14 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.87M$2.51B$5.12B$9.07BDividend YieldN/A0.73%4.91%4.22%P/E RatioN/A6.0791.3417.19Price / Sales52.0075.081,117.70116.80Price / CashN/A15.0542.6437.86Price / Book0.883.284.794.78Net Income-$27.78M$29.98M$120.07M$225.60M7 Day Performance-5.60%-1.55%-1.90%-1.23%1 Month Performance-17.98%8.21%11.45%3.37%1 Year Performance-23.16%-21.46%30.63%16.58% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte3.2596 of 5 stars$2.19-0.9%$4.42+101.7%-22.1%$36.87M$709,000.000.00120Analyst ForecastGap DownPBYIPuma Biotechnology3.9481 of 5 stars$3.02+4.9%$7.00+131.8%-30.0%$148.25M$243.57M6.42185Positive NewsTILInstil Bio2.8565 of 5 stars$22.21+1.1%$145.00+552.9%+196.5%$144.94MN/A-1.9149BDTXBlack Diamond Therapeutics2.361 of 5 stars$2.55-0.4%$15.50+507.8%-16.2%$144.29MN/A-1.9290Positive NewsGap DownGALTGalectin Therapeutics1.9706 of 5 stars$2.28+8.1%$11.00+382.5%-39.2%$143.09MN/A-3.149News CoverageGap DownHigh Trading VolumeELUTElutia2.7375 of 5 stars$4.14flat$10.00+141.5%+148.2%$143.08M$24.75M-1.59180CGENCompugen1.5938 of 5 stars$1.60-0.9%$4.00+150.8%-17.3%$142.33M$59.85M80.5068TELOTelomir PharmaceuticalsN/A$4.80-7.7%N/AN/A$142.13MN/A0.001High Trading VolumeJATTJATT AcquisitionN/A$8.16-24.1%N/A-51.6%$140.76MN/A0.003High Trading VolumeENTAEnanta Pharmaceuticals4.0469 of 5 stars$6.50+7.8%$19.50+200.0%-26.3%$137.76M$67.64M-1.10145MNPRMonopar Therapeutics1.9712 of 5 stars$26.09+2.8%$27.33+4.8%+1,165.4%$137.70MN/A-12.8810News Coverage Related Companies and Tools Related Companies Puma Biotechnology Alternatives Instil Bio Alternatives Black Diamond Therapeutics Alternatives Galectin Therapeutics Alternatives Elutia Alternatives Compugen Alternatives Telomir Pharmaceuticals Alternatives JATT Acquisition Alternatives Enanta Pharmaceuticals Alternatives Monopar Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCX Stock Alerts